Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study

Musso, Maurizio; Scalone, Renato; Marcacci, Gianpaolo; Lanza, Francesco; Renzo, Nicola Di; Cascavilla, Nicola; Bartolomeo, Paolo Di; Crescimanno, Alessandra; Perrone, Tania; Pinto, Antonello

doi:10.1038/bmt.2009.318

Cited by 40 publications

(48 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[49,50] Unlike other nitrosoureas, fotemustine has shown no significant pulmonary toxicity and may therefore be a reasonable alternative to carmustine.…”

Section: Feammentioning

confidence: 98%

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning

Isidori¹,

Christofides

Visani³

2016

Leukemia & Lymphoma

View full text Add to dashboard Cite

High-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) is the standard treatment for relapsed or refractory non-Hodgkin and Hodgkin lymphoma. Until recently, carmustine, etoposide, cytarabine and melphalan (BEAM) was the most commonly used conditioning regimen in this setting, given its acceptable efficacy and tolerability. Despite reasonable success with BEAM, carmustine is associated with a number of acute and late toxicities. Moreover, recent supply and cost issues for this agent have created an urgent need for alternative conditioning regimens. As such, etoposide and melphalan (VP16/MEL) or busulfan, cyclophosphamide, and etoposide (BuCyE) are currently being used with limited success. A number of novel conditioning regimens that replace carmustine with other agents are under investigation, which may provide effective alternatives to BEAM. In considering novel agents to replace carmustine, bendamustine may provide the best alternative, as demonstrated by the results of a number of phase II, multicenter, controlled studies.

show abstract

“…[49,50] Unlike other nitrosoureas, fotemustine has shown no significant pulmonary toxicity and may therefore be a reasonable alternative to carmustine.…”

Section: Feammentioning

confidence: 98%

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning

Isidori¹,

Christofides

Visani³

2016

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…15,[18][19][20] Clinical outcomes and survival after ASCT depend on disease chemosensitivity at transplant, the efficacy of the conditioning regimen at eradicating the residual tumor cell clone after salvage chemotherapy, and transplant-related mortality and morbidity. 9,18,15,20,21 At a median follow-up of 27 months (range, 8 to 60 mo), the median DFS in our group was 20 months (range, 4 to 60 mo). With a follow-up of more than 2 years, the DFS was 77% (23/30 patients), and the 2-year OS was 84% (25/30 patients).…”

Section: Discussionmentioning

confidence: 99%

Autologous Noncryopreserved Hematopoietic Stem Cell Transplant With CEAM as a Modified Conditioning Regimen in Patients With Hodgkin Lymphoma: A Single-center Experience With a New Protocol

Ramzi

Mohamadian

Vojdani

et al. 2012

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…Regimens avoiding BCNU by using high-dose melphalan or melphalan with etoposide and cyclophosphamide have been reported Guilcher et al 2012 ;Schutt et al 2007 ). Modifi ed BEAM regimens have substituted alternative chloroethylnitrosureas for BCNU, including fotemustine and lomustine (Musso et al 2010 ;Ramzi et al 2012 ), although neither regimen has supplanted traditional BEAM.…”

Section: Conditioning Regimens For Autologous Hctmentioning

confidence: 99%

Lymphomas

O’Brien¹,

Absalon²,

Gross³

et al. 2013

Pediatric Oncology

View full text Add to dashboard Cite

Lymphomas are the third most common malignancy in children and adolescents, after acute leukemias and brain tumors; they account for approximately 15 % of all pediatric cancers (Howlader et al. 2012 ). Among children <15 years of age, non-Hodgkin lymphomas (NHL) predominate, accounting for approximately 6 % of childhood cancers, while Hodgkin lymphoma (HL) is more rare (3.6 %). In older adolescents, Hodgkin lymphoma incidence increases signifi cantly, such that it represents 17 % of new cancer diagnoses compared to 8.3 % for NHL (Howlader et al. 2012 ). Fortunately, lymphomas are among the most curable of childhood cancers, with 5-year survival rates improving substantially from 1975 (44 % for NHL, 82 % for HL) to 2006 (80 % for NHL, 95 % for HL) (Smith et al. 2010 ). In NHL, improved understanding of the biology of different subtypes (lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and anaplastic large cell lymphoma) has led to refi ned treatment strategies. In HL, advances in risk-and response-adapted chemotherapy and radiation therapy have contributed to high cure rates for newly diagnosed patients. As a result, there is

show abstract

Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study

Abstract: The NCI Common Terminology Criteria for Adverse Events v3.0 is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term.

Cited by 40 publications

References 35 publications

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning

Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning

Autologous Noncryopreserved Hematopoietic Stem Cell Transplant With CEAM as a Modified Conditioning Regimen in Patients With Hodgkin Lymphoma: A Single-center Experience With a New Protocol

Lymphomas

Contact Info

Product

Resources

About